iMBP is honored to work with top experts and industry leaders helping advance our mission to revolutionize the biopharma industry
With over 22 years of industry business and research experience, Dr. Urban A. Kiernan is the Founder, Chairman and CEO of iMetabolic Biopharma Corporation (iMBP).
He is a seasoned BioTech leader with decades of industry business and scientific research experience. However, his passion is what drives him beyond what any academic or work experience could ever afford him.
He received his M.Sc. and Ph.D. from Arizona State University, is a devoted husband, father and Jiu Jitsuka. He has authored more than 45 peer reviewed publications, 4 book chapters and received 11 patent awards…and there is more to come!
Urban, together with an amazing team of experts, are continuously working on the innovative iPlatform™ biotechnology.
Dr. Munk has over 25 years of experience in the life science and pharmaceutical industry. He currently serves as the Deputy Director of the Biodesign Institute at Arizona State University, but spent the last two decades as the CEO of Ash Stevens Inc, a full service Active Pharmaceutical Ingredient (API) development & manufacturing organization.
Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances and received six NIH research contacts. He received his B.S. degree in chemistry at ASU, and then earned his Ph.D. in organic synthesis at The University of California at Berkeley. He is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager.
David Hendren has extensive experience launching, financing, and building successful ventures from incubation to exit, with particular expertise in healthcare, life science, biomedical technology, digital health, and related technology and service areas.
He has deep knowledge and broad perspective from 25+ years in leadership roles on virtually all sides of the table, including VC, entrepreneur, CEO, board member/chair, advisor, consultant, and counsel. David has launched successful medical technologies from inception, and led, co-invested and executed deals with leading firms and strategics, with exits including IPO, M&A, and technology licensing transactions cumulatively exceeding $1B. He earned his AB at Dartmouth College and his JD at Northwestern University Pritzker School of Law.
Jeffrey Zimmerman practiced law for 44 years with emphasis in business and entrepreneurship. He received his undergraduate degree in 1974 from Fort Hays Kansas State University and his Juris Doctor degree from the University of Kansas in 1977.
Jeff has served as general counsel to several corporations. He also served as president of several corporations he had a role in founding. He has assisted in the merger or acquisition of several businesses. He currently serves on the board of directors of three for-profit corporations and serves on several not-for-profit charitable and arts boards.
Jeff is a graduate of the Kauffman Foundation Center for Entrepreneurial Studies Fast Track Entrepreneurial Training Program and has handled numerous multi million dollar business sales and acquisitions and is well versed in all area business finance.
Nathan oversees a variety of business functions for iMBP as it relates to international strategic partnerships. In 2021, he left another industry to follow Dr. Urban Kiernan and iMBP on an incredibly inspirational journey to change the world!
His background in Global Business Development from other industries including Health & Wellness, Telecommunications, and Education has served him well in the transition to biotechnology. With working business relationships in 24 different countries, he very happy with iMBP's early success in international expansion and forecast significant growth for iMBP in 2023 and beyond!
Dr. Wilson earned his Ph.D. at Arizona State University where he pushed the boundary of computations and biology by building computational models of the immune system. Post Ph.D., his interests have evolved into supporting the development of iMBP and the iPlatform™ by combining physics-based simulations and machine learning to help usher in a new era of drug development. Harnessing the power of these technologies has significant potential to accelerate the discovery of new biology-inspired therapeutics and makes my role at iMBP both exciting and fulfilling.